Edward Eden1, Radmila Choate2, Alan Barker3, Doreen Addrizzo-Harris4, Timothy R Aksamit5, Charles L Daley6, M Leigh Anne Daniels7, Angela DiMango8, Kevin Fennelly9, David E Griffith10, Margaret M Johnson11, Michael R Knowles7, Mark L Metersky12, Peadar G Noone7, Anne E O'Donnell13, Kenneth N Olivier9, Matthias A Salathe14, Andreas Schmid15, Byron Thomashow8, Gregory Tino16, Gerard M Turino1, Kevin L Winthrop3,17. 1. Icahn School of Medicine Mt Sinai, New York, New York. 2. University of Kentucky College of Public Health, Lexington. 3. Oregon Health Sciences University Hospital, Portland. 4. New York University School of Medicine, New York. 5. Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. 6. Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado. 7. University of North Carolina at Chapel Hill. 8. Columbia College of Physicians and Surgeons, Center for Chest Disease, New York, New York. 9. National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. 10. University of Texas at Tyler. 11. Mayo Clinic Florida, Pulmonary and Critical Care, Jacksonville. 12. Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farmington. 13. Georgetown University Medical Center, Washington, DC. 14. University of Kansas Medical School, Kansas City. 15. University of Miami Miller School of Medicine, Miami, Florida. 16. University of Pennsylvania Perelman School of Medicine, Philadelphia. 17. Department of Infectious Disease, Oregon Health and Science University School of Medicine, Portland.
Abstract
OBJECTIVE: This study compares and contrasts the clinical features of non-cystic fibrosis bronchiectasis with 3 uncommon disorders known to be associated with bronchiectasis but with distinctly different underlying defined pathophysiologic derangements, namely severe alpha-1 antitrypsin deficiency (AATD), common variable immunodeficiency (CVI) and primary ciliary dyskinesia (PCD). METHODS: The Bronchiectasis Research Registry provides a central database for studying patients with non-cystic fibrosis bronchiectasis. This report consists of information from 13 U.S. sites pertaining to the 3 study diagnoses. Patients with AATD (SZ and ZZ phenotypes only), CVI (patients with IgG≤500), PCD (history of physician diagnosed Kartagener's syndrome or PCD), and patients with confirmed absence of the above 3 diagnoses (idiopathic control group) were included in the study. Descriptive statistics were computed for the main demographic and clinical characteristics of the sample stratified by group. Values between the groups were compared using Kruskal-Wallis test, and Chi-squared/ Fisher's exact tests respectively. The significance level was set at 0.05. Software SAS 9.4 was used to perform the statistical analyses. RESULTS: Of the 2170 participants in the database enrolled as of January 2017, 615 respondents had sufficient data and were included in the analyses. Patients with PCD (n=79, mean age 41.9 years [standard deviation (SD)=14.5]) were significantly younger than patients with AATD (n=58, mean age 66.9 [SD=10.7]), CVI (n=18, mean age 66.7 years [SD=10.5]) or the idiopathic group (n=460, mean age 64.2 [SD=15.9]), p<.0001. Compared to other groups, those with PCD had lower pulmonary function (forced expiratory volume in 1 second [FEV1] forced vital capacity [FVC] and FEV1/FVC ratio) (p<0.01), and a greater proportion of them reported having exacerbations and/or hospitalizations in the past 2 years (p<0.01). Overall, Pseudomonas aeruginosa and Staphylococcus aureus were the organisms most commonly isolated from sputum. Mycobacterial infection was most commonly reported in those with AATD. CONCLUSION: This report from the U.S. Bronchiectasis Research Registry compares and contrasts differences in the clinical features of patients suffering from 3 rare conditions, with different underlying causes, to those without. The group with PCD had more symptoms, greater morbidity, lower lung function and more commonly were infected by Pseudomonas aeruginosa. A greater percentage of those with AATD reported mycobacterial lung involvement. JCOPDF
OBJECTIVE: This study compares and contrasts the clinical features of non-cystic fibrosis bronchiectasis with 3 uncommon disorders known to be associated with bronchiectasis but with distinctly different underlying defined pathophysiologic derangements, namely severe alpha-1 antitrypsin deficiency (AATD), common variable immunodeficiency (CVI) and primary ciliary dyskinesia (PCD). METHODS: The Bronchiectasis Research Registry provides a central database for studying patients with non-cystic fibrosis bronchiectasis. This report consists of information from 13 U.S. sites pertaining to the 3 study diagnoses. Patients with AATD (SZ and ZZ phenotypes only), CVI (patients with IgG≤500), PCD (history of physician diagnosed Kartagener's syndrome or PCD), and patients with confirmed absence of the above 3 diagnoses (idiopathic control group) were included in the study. Descriptive statistics were computed for the main demographic and clinical characteristics of the sample stratified by group. Values between the groups were compared using Kruskal-Wallis test, and Chi-squared/ Fisher's exact tests respectively. The significance level was set at 0.05. Software SAS 9.4 was used to perform the statistical analyses. RESULTS: Of the 2170 participants in the database enrolled as of January 2017, 615 respondents had sufficient data and were included in the analyses. Patients with PCD (n=79, mean age 41.9 years [standard deviation (SD)=14.5]) were significantly younger than patients with AATD (n=58, mean age 66.9 [SD=10.7]), CVI (n=18, mean age 66.7 years [SD=10.5]) or the idiopathic group (n=460, mean age 64.2 [SD=15.9]), p<.0001. Compared to other groups, those with PCD had lower pulmonary function (forced expiratory volume in 1 second [FEV1] forced vital capacity [FVC] and FEV1/FVC ratio) (p<0.01), and a greater proportion of them reported having exacerbations and/or hospitalizations in the past 2 years (p<0.01). Overall, Pseudomonas aeruginosa and Staphylococcus aureus were the organisms most commonly isolated from sputum. Mycobacterial infection was most commonly reported in those with AATD. CONCLUSION: This report from the U.S. Bronchiectasis Research Registry compares and contrasts differences in the clinical features of patients suffering from 3 rare conditions, with different underlying causes, to those without. The group with PCD had more symptoms, greater morbidity, lower lung function and more commonly were infected by Pseudomonas aeruginosa. A greater percentage of those with AATD reported mycobacterial lung involvement. JCOPDF
Authors: J Angrill; C Agustí; R de Celis; A Rañó; J Gonzalez; T Solé; A Xaubet; R Rodriguez-Roisin; A Torres Journal: Thorax Date: 2002-01 Impact factor: 9.139
Authors: Jeung Sook Kim; Nobuyuki Tanaka; John D Newell; Mary A Degroote; Kayte Fulton; Gwen Huitt; David A Lynch Journal: Chest Date: 2005-12 Impact factor: 9.410
Authors: James K Stoller; Robert A Sandhaus; Gerard Turino; Ryan Dickson; Keith Rodgers; Charlie Strange Journal: Chest Date: 2005-10 Impact factor: 9.410
Authors: Benjamin Gathmann; Nizar Mahlaoui; Laurence Gérard; Eric Oksenhendler; Klaus Warnatz; Ilka Schulze; Gerhard Kindle; Taco W Kuijpers; Rachel T van Beem; David Guzman; Sarita Workman; Pere Soler-Palacín; Javier De Gracia; Torsten Witte; Reinhold E Schmidt; Jiri Litzman; Eva Hlavackova; Vojtech Thon; Michael Borte; Stephan Borte; Dinakantha Kumararatne; Conleth Feighery; Hilary Longhurst; Matthew Helbert; Anna Szaflarska; Anna Sediva; Bernd H Belohradsky; Alison Jones; Ulrich Baumann; Isabelle Meyts; Necil Kutukculer; Per Wågström; Nermeen Mouftah Galal; Joachim Roesler; Evangelia Farmaki; Natalia Zinovieva; Peter Ciznar; Efimia Papadopoulou-Alataki; Kirsten Bienemann; Sirje Velbri; Zoya Panahloo; Bodo Grimbacher Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793
Authors: David G Parr; Peter G Guest; John H Reynolds; Lee J Dowson; Robert A Stockley Journal: Am J Respir Crit Care Med Date: 2007-09-13 Impact factor: 21.405
Authors: Edward D Chan; Aleksandra M Kaminska; Wendy Gill; Kathryn Chmura; Nicole E Feldman; Xiyuan Bai; Corinne M Floyd; Kayte E Fulton; Gwen A Huitt; Matthew J Strand; Michael D Iseman; Leland Shapiro Journal: Scand J Infect Dis Date: 2007
Authors: Stefano Aliberti; Sara Lonni; Simone Dore; Melissa J McDonnell; Pieter C Goeminne; Katerina Dimakou; Thomas C Fardon; Robert Rutherford; Alberto Pesci; Marcos I Restrepo; Giovanni Sotgiu; James D Chalmers Journal: Eur Respir J Date: 2016-02-04 Impact factor: 16.671
Authors: Ashwin Basavaraj; Radmila Choate; Doreen Addrizzo-Harris; Timothy R Aksamit; Alan Barker; Charles L Daley; M Leigh Anne Daniels; Edward Eden; Angela DiMango; Kevin Fennelly; David E Griffith; Margaret M Johnson; Michael R Knowles; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Kevin L Winthrop Journal: Chest Date: 2020-07-03 Impact factor: 9.410
Authors: José Luis Lopez-Campos; Lourdes Osaba; Karen Czischke; José R Jardim; Mariano Fernandez Acquier; Abraham Ali; Hakan Günen; Noelia Rapun; Estrella Drobnic; Marc Miravitlles Journal: Respir Res Date: 2022-06-10
Authors: Jessica Rademacher; Sabine Dettmer; Jan Fuge; Jens Vogel-Claussen; Hoen-Oh Shin; Anand Shah; Paula Inês Pedro; Rob Wilson; Tobias Welte; Frank Wacker; Michael R Loebinger; Felix C Ringshausen Journal: Respiration Date: 2021-04-23 Impact factor: 3.580
Authors: Florian Gahleitner; James Thompson; Claire L Jackson; Jana F Hueppe; Laura Behan; Eleonora Dehlink; Myrofora Goutaki; Florian Halbeisen; Ana Paula L Queiroz; Guillaume Thouvenin; Claudia E Kuehni; Philipp Latzin; Jane S Lucas; Bruna Rubbo Journal: ERJ Open Res Date: 2021-11-29
Authors: Lawrence E Ostrowski; Weining Yin; Amanda J Smith; Patrick R Sears; Ximena M Bustamante-Marin; Hong Dang; Friedhelm Hildebrandt; Leigh Anne Daniels; Nicole A Capps; Kelli M Sullivan; Margaret W Leigh; Maimoona A Zariwala; Michael R Knowles Journal: Int J Mol Sci Date: 2022-02-03 Impact factor: 6.208
Authors: Troy D Rogers; Brian Button; Samir N P Kelada; Lawrence E Ostrowski; Alessandra Livraghi-Butrico; Mark I Gutay; Charles R Esther; Barbara R Grubb Journal: Front Physiol Date: 2022-03-09 Impact factor: 4.566
Authors: Alessandro Sanduzzi; Emanuele Ciasullo; Ludovica Capitelli; Stefano Sanduzzi Zamparelli; Marialuisa Bocchino Journal: Int J Environ Res Public Health Date: 2020-03-29 Impact factor: 3.390
Authors: J Raidt; J Brillault; F Brinkmann; A Jung; C Koerner-Rettberg; A Koitschev; H Linz-Keul; T Nüßlein; F C Ringshausen; J Röhmel; M Rosewich; C Werner; H Omran Journal: Pneumologie Date: 2020-09-25